An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01333007

ML22991

Details and patient eligibility

About

This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.

Enrollment: 423 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
• Treating physician's decision to initiate first-line Avastin treatment

Exclusion criteria

• Participation in a clinical trial evaluating anti-cancer therapies

Trial design

423 participants in 1 patient group

Cohort